NPS Reports Disappointing Drug Results

NPS Pharmaceuticals Inc. (NPSP) reported disappointing results from a late stage clinical trial for its short bowel syndrome treatment Gattex. Shares of the biopharmaceutical plunged $1.47 to close at $4.21.